- Home
- TC vs PASG Comparison
TC vs PASG Comparison
Compare TC & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | PASG |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | China | United States |
| Employees | N/A | 27 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 26.0M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TC | PASG |
|---|---|---|
| Price | $10.30 | $6.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 2.7K | ★ 28.8K |
| Earning Date | 03-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.28 |
| 52 Week High | $19.99 | $20.00 |
Technical Indicators
Market Signals| Indicator | TC | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 35.61 |
| Support Level | $8.93 | $6.71 |
| Resistance Level | $11.00 | $7.72 |
| Average True Range (ATR) | 0.56 | 0.73 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 6.95 | 18.01 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.